CN116924906A - 一种新型长效ffa1激动剂、其制备方法及其作为药物的用途 - Google Patents
一种新型长效ffa1激动剂、其制备方法及其作为药物的用途 Download PDFInfo
- Publication number
- CN116924906A CN116924906A CN202210340242.XA CN202210340242A CN116924906A CN 116924906 A CN116924906 A CN 116924906A CN 202210340242 A CN202210340242 A CN 202210340242A CN 116924906 A CN116924906 A CN 116924906A
- Authority
- CN
- China
- Prior art keywords
- hex
- ynoic acid
- biphenyl
- phenyl
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150108864 Ffar1 gene Proteins 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 101100264077 Xenopus laevis wrn gene Proteins 0.000 title abstract description 22
- 239000000556 agonist Substances 0.000 title abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 4
- 230000002159 abnormal effect Effects 0.000 claims abstract 4
- 230000004153 glucose metabolism Effects 0.000 claims abstract 2
- -1 3- ([ 1,1' -biphenyl ] -3-yl) hex-4-ynoic acid Chemical compound 0.000 claims description 178
- 150000001875 compounds Chemical class 0.000 claims description 38
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 208000004930 Fatty Liver Diseases 0.000 claims description 11
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 208000010706 fatty liver disease Diseases 0.000 claims description 10
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- VTZDPQGGOUEESD-UHFFFAOYSA-N 4-hexynoic acid Chemical compound CC#CCCC(O)=O VTZDPQGGOUEESD-UHFFFAOYSA-N 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 230000036407 pain Effects 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- MVFHRQWYCXYYMU-UHFFFAOYSA-N 3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1C1=CC=CC=C1 MVFHRQWYCXYYMU-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- NKWHZLOVLHDGAC-UHFFFAOYSA-N CC#CC(CC(=O)O)C1=CC=C(C=C1)C2=CC=CC=C2 Chemical compound CC#CC(CC(=O)O)C1=CC=C(C=C1)C2=CC=CC=C2 NKWHZLOVLHDGAC-UHFFFAOYSA-N 0.000 claims description 4
- 206010006895 Cachexia Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- NULJZZQMTQVLPG-UHFFFAOYSA-N n,n-dimethylmorpholin-4-amine Chemical compound CN(C)N1CCOCC1 NULJZZQMTQVLPG-UHFFFAOYSA-N 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 3
- 206010008635 Cholestasis Diseases 0.000 claims description 3
- 208000002249 Diabetes Complications Diseases 0.000 claims description 3
- 206010012655 Diabetic complications Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
- 208000001280 Prediabetic State Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000012268 mitochondrial disease Diseases 0.000 claims description 2
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 10
- 241000699670 Mus sp. Species 0.000 description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 230000000694 effects Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 208000000114 Pain Threshold Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- NJYJBYPNDWNZAH-UHFFFAOYSA-N 2-[2-fluoro-4-[[3-(2-methylphenyl)phenyl]methoxy]phenoxy]acetic acid Chemical compound FC1=C(OCC(=O)O)C=CC(=C1)OCC=1C=C(C=CC=1)C1=C(C=CC=C1)C NJYJBYPNDWNZAH-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 6
- 229960001395 fenbufen Drugs 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 230000001270 agonistic effect Effects 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000001853 liver microsome Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- JUOJESMBZPRKIA-UHFFFAOYSA-N 2-(4-phenylphenyl)sulfanylacetic acid Chemical compound C1=CC(SCC(=O)O)=CC=C1C1=CC=CC=C1 JUOJESMBZPRKIA-UHFFFAOYSA-N 0.000 description 3
- LXRDFDDOMVFUNV-UHFFFAOYSA-N 2-(4-phenylphenyl)sulfonylacetic acid Chemical compound C1=CC(S(=O)(=O)CC(=O)O)=CC=C1C1=CC=CC=C1 LXRDFDDOMVFUNV-UHFFFAOYSA-N 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- FKPYNBFWCSTPOT-UHFFFAOYSA-N methyl 3-(4-bromophenyl)propanoate Chemical compound COC(=O)CCC1=CC=C(Br)C=C1 FKPYNBFWCSTPOT-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 235000020925 non fasting Nutrition 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002955 secretory cell Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- JJKMIZGENPMJRC-UHFFFAOYSA-N 3-oxo-3-propan-2-yloxypropanoic acid Chemical compound CC(C)OC(=O)CC(O)=O JJKMIZGENPMJRC-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- QBNOPZJAURRQCE-UHFFFAOYSA-M magnesium;prop-1-yne;bromide Chemical compound [Mg+2].[Br-].CC#[C-] QBNOPZJAURRQCE-UHFFFAOYSA-M 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/38—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
- C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一类新型长效FFA1激动剂、其制备方法及含有该衍生物的药物组合物作为制备预防或/和治疗葡萄糖代谢异常或/和脂质代谢异常疾病的药物用途。
Description
技术领域
本发明涉及一种新型长效FFA1激动剂、其制备方法及其应用,属于医药技术领域。本发明中涉及的化合物在该领域具有新颖性和独特性。
背景技术
代谢综合征是以胰岛素抵抗和内脏脂肪堆积为特征的常见病,伴有低密度脂蛋白升高和高密度脂蛋白胆固醇降低,其常见的病症为肥胖病、糖尿病、高血脂症、动脉粥样硬化和脂肪肝等,其中,糖尿病患者还常并发有高脂血症、心血管病、糖尿病肾病、糖尿病神经病变等疾病。代谢综合征可以通过饮食调节和锻炼治疗,当这些不能缓解症状时,需要进行药物治疗。在代谢综合症的药物治疗方面,目前临床使用的降糖药或降脂药等作用单一,难以达到同时改善代谢综合征各项病理指标的作用。因此,针对代谢综合征的多重机制药物研究正在进行,以期为代谢综合征患者带来更安全有效的新型药物。
糖尿病已逐渐成为严重威胁人类健康的代谢综合征,开发具有全新机制的降糖药物显得十分必要。FFA1作为糖尿病研究领域的热门靶点,受到了全球工业界及学术界的广泛关注,有大量高活性的FFA1调节剂陆续被报道。尽管目前在FFA1激动剂及拮抗剂的选择上仍有争议,但FFA1激动剂在糖尿病治疗方面已经得到临床概念验证并成为共识。FFA1用于糖尿病治疗具有多种优势:1)由于FFA1能够以葡萄糖依赖性地方式促进胰岛素释放,故其激动剂具有较低的低血糖风险;2)FFA1主要分布于胰岛β细胞及肠分泌细胞,因此导致全身副反应的可能性较小;3)肠道分泌细胞中的FFA1能够促进GLP-1分泌,有助于控制体重以及降低胰岛β细胞损伤,与GLP-1类降糖药物有着异曲同工之妙。最近研究表明,激活脑部FFA1还可改善疼痛、阿尔兹海默症、癌症恶病质等病症。
本发明涉及结构新颖的FFA1激动剂,其具有优异的体内外药理活性。因此,所述FFA1激动剂及其可药用盐可以潜在的用于治疗或者预防糖尿病、脂肪肝、疼痛等疾病,具有广阔的药物开发前景。
发明内容
本发明的目的是提供一种疗效更好,代谢更稳定的FFA1激动剂,为预防或/和治疗糖尿病、糖尿病并发症、前驱糖尿病、脂肪肝、胆汁淤积性肝病、肝移植物抗宿主病、病毒引起的慢性肝病、酒精性肝病、药物性肝损伤、高脂血症、肥胖、代谢综合征、动脉粥样硬化、器官纤维化、炎症、阿尔兹海默症、疼痛、癌症恶病质及癌症等疾病提供一类新的潜在药物。本发明人完全通过自身大量研究、实践和经验,优选出本发明所述的FFA1激动剂,其具有意想不到的药理学特征。
本发明一方面提供了以下化合物(I)或其药学可接受的盐、前药、酯和溶剂合物,其中所述的盐包括药学可接受的钠盐、钾盐、有机碱盐等;前药包括药学可接受的羧酸酯、酰胺等。
其中:
A、B环为各自独立的取代或未取代的苯环、芳杂环;
R1、R2、R3和R4相同或不同,并各自为H、F、Cl、环丙基、二甲氨基、吗啉、哌啶、四氢吡咯、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷基-O-;
R选自H、环丙基、丙炔基。
本发明化合物优选自:
A、B环为各自独立的取代或未取代的苯环、芳杂环;
R1优选自H、F、Cl;
R2、R3和R4相同或不同,并各自为H、F、Cl、环丙基、二甲氨基、吗啉、哌啶、四氢吡咯、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷基-O-;
R选自H、环丙基、丙炔基。
本发明涉及的化合物或药学可接受的盐、前药、酯和溶剂合物作为FFA1激动剂的用途。
本发明的另一方面涉及一种药物组合物,其含有治疗有效剂量的所述化合物或其药学可接受的盐、前药、酯和溶剂合物,及适当的载体、稀释剂或赋形剂。
本发明同时涉及所述化合物或其药学可接受的盐、前药、酯和溶剂合物用于制备药物的用途,其中所述药物用于治疗、预防或缓解一种或多种疾病或功能障碍,所述一种或多种疾病或功能障碍选自糖尿病、肥胖症、高血脂、炎症性肠病、疼痛、癌症恶病质、阿尔兹海默症、胆汁淤积性肝病、线粒体病、酒精性肝病、药物性肝损伤、糖尿病并发症、前驱糖尿病、器官纤维化、动脉粥样硬化及脂肪肝。
发明的详细说明
除非另有说明,否则下列用在说明书和权利要求书中的术语具有下述含义。
本文中所示的任何通式或结构,包括通式(I)的化合物在内,还意在表示所述化合物的未标记形式和同位素标记的形式。同位素标记的化合物具有本文给出的分子式所示的结构,除了一个或多个原子被具有选定原子质量或质量数的原子替代。本发明的化合物中可包含的同位素的实例包括氢、碳、氮、氧、氟和氯的同位素,在本发明的化合物中,未明确指明为特定同位素的任何原子意在表示该原子的任何稳定的同位素。除非另外说明,当明确以“H”或“氢”标明某位置时,应理解为该位置为其同位素组成的氢。因此,在本发明的化合物中,明确标明氘(D)的任何原子意在表示氘。
“药物组合物”表示含有一种或多种本发明所述化合物或其可药用的盐,或其前药与其他化学组分的混合物,其他化学组分例如可药用的载体和赋形剂。药物组合物的目的是促进生物体对活性成分的吸收,利于活性成分在生物体内发挥生物活性。
附图说明
图1:ZLY50对三种经典疼痛模型的镇痛疗效,***P≤0.001为相对于模型对照组的统计学检验结果。
图2:ZLY50(一周一次给药)长期给药对ob/ob小鼠血糖、口服糖耐量的影响。
图3:ZLY50(一周一次给药)长期给药对ob/ob小鼠脂肪肝、血脂、肝脏脂质水平的影响。
图4:ZLY50(一周一次给药)长期给药对db/db小鼠脂肪肝、血脂、肝脏脂质水平的影响。
具体实施方式
下面结合实施例对本发明作进一步说明。需要说明的是,下述实施例仅是用于说明,而并非用于限制本发明。本领域技术人员根据本发明的教导所做出各种变化均应在本申请权利要求的保护范围之内。
实施例1
3-([1,1′-联苯]-4-基)丙酸(1)
将3-(4-溴苯基)丙酸甲酯(1a)(0.50g,2.70mmol),苯硼酸(0.43g,3.51mmol)溶于15ml混合溶剂中(水/乙醇/甲苯,3∶1∶3,v/v),依次加入碳酸钠(0.86g,8.11mmol),Pd(PPh3)4(0.15g,0.14mmol),所得混合液于氮气保护下加热80℃反应24h,冷却至室温,加水20ml稀释,以硅藻土做铺垫抽滤,乙酸乙酯(15ml×3)洗涤滤饼,滤液以乙酸乙酯(20ml×3)萃取,合并有机相以饱和NaCl溶液(20ml×2)洗涤,所得有机相以无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,残余物经柱层析(石油醚/乙酸乙酯,95∶5,v/v)纯化得到白色固体0.62g,收率96%。将上述得到的酯(0.62g,2.58mmol)溶于3mL四氢呋喃,3mL甲醇和1mL水中,加入LiOH·H2O(0.2g,4.8mmol),室温反应4h,减压蒸除四氢呋喃和甲醇,冰水浴下滴加1N稀盐酸调节pH 2-3,析出白色固体,抽滤,干燥得白色粉末状固体(1)0.57g,熔点125-126℃,收率83%。
1H NMR(400MHz,DMSO-d6)δ12.17(s,1H),7.67-7.61(m,2H),7.57(d,J=8.2Hz,2H),7.49-7.44(m,2H),7.38-7.34(m,1H),7.32(d,J=8.2Hz,2H),2.87(t,J=7.6Hz,2H),2.58(t,J=7.6Hz,2H).13C NMR(101MHz,DMSO-d6)δ174.17,140.64,140.52,138.40,129.33,129.29,127.64,127.05,126.96,35.60,30.43.TOF MS m/z:calcd.for C15H13O2 -[M-H]-:225.0921;found 225.0934.
实施例2
2-((3-氟-[1,1′-联苯]-4-基)氧基)乙酸(2)
7.40(m,3H),7.39-7.31(m,1H),7.15(t,J=8.8Hz,1H),4.83(s,2H).13C NMR(75MHz,DMSO-d6)δ170.32,152.24(d,J=243.8Hz),145.61(d,J=10.7Hz),139.04(d,J=1.8Hz),134.20(d,J=6.6Hz),129.43,127.85,126.84,123.03(d,J=3.3Hz),115.60(d,J=2.1Hz),114.79(d,J=18.9Hz),65.55.TOF MS m/z:calcd.for C14H10FO3 -[M-H]-:245.0619;found 245.0617.
实施例3
2-([1,1′-联苯]-4-基硫基)乙酸(3)
1H),3.86(s,2H).13C NMR(101MHz,DMSO-d6)δ170.99,139.82,138.20,135.49,129.42,128.73,127.91,127.65,126.88,35.43.TOF MS m/z:calcd.for C14H11O2S-[M-H]-:243.0485;found 243.0481.
实施例4
2-([1,1′-联苯]-4-基磺酰基)乙酸(4)
机相以饱和NaCl溶液(20ml×2)洗涤,所得有机相以无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色油状液体0.22g,收率65%。将上述得到酯(0.22g,2.58mmol)溶于3mL四氢呋喃,3mL甲醇和1mL水中,加入LiOH·H2O(0.2g,4.8mmol),室温反应4h,减压蒸除四氢呋喃和甲醇,冰水浴下滴加1N稀盐酸调节pH 2-3,析出白色固体,抽滤,干燥得白色粉末状固体(4)0.20g,熔点92-94℃,收率96%。1H NMR(400MHz,DMSO-d6)δ8.02(d,J=8.6Hz,2H),7.96(d,J=8.6Hz,2H),7.81-7.73(m,2H),7.56-7.51(m,2H),7.49-7.44(m,1H),4.56(s,2H).13C NMR(101MHz,DMSO-d6)δ164.43,145.86,138.74,138.50,129.64,129.21,127.78,127.66,60.54.TOF MS m/z:calcd.for C14H11O4S-[M-H]-:275.0384;found275.0394.
实施例5
3-([1,1′-联苯]-4-基)己-4-炔酸(5)
将对溴苯甲醛(0.50g,2.70mmol),苯硼酸(0.43g,3.51mmol)溶于15ml混合溶剂中(水/乙醇/甲苯,3∶1∶3,v/v),依次加入碳酸钠(0.86g,8.11mmol),Pd(PPh3)4(0.16g,0.14mmol),所得混合液于氮气保护下加热80℃反应24h,冷却至室温,加水20ml稀释,以硅藻土做铺垫抽滤,乙酸乙酯(15ml×3)洗涤滤饼,滤液以乙酸乙酯(30ml×4)萃取,合并有机相以饱和NaCl溶液(20ml×2)洗涤,所得有机相以无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,残余物经柱层析(石油醚/乙酸乙酯,95∶5,v/v)纯化得到白色固体(5b)0.47g,收率95%。5b(0.47g,2.58mmol),丙二酸环(亚)异丙酯(0.48g,3.35mmol)溶于10ml四氢呋喃中,加入催化量DMAP,室温搅拌12h,TLC检测反应完毕后,将反应液倒入10ml水中,乙酸乙酯(20ml×3)萃取,合并有机相,以饱和食盐水(15ml×2)洗涤,无水硫酸钠干燥,过滤,滤液减压蒸除溶剂,经重结晶(无水乙醇)得到黄色固体(5c)0.44g,收率56%。
5c(0.35g,1.14mmol)溶于10ml无水四氢呋喃中,在氮气氛围下,冰浴冷却下滴加1-丙炔溴化镁(2.3ml,1.15mmol),滴毕,所得溶液升至室温反应0.5h,TLC检测反应完毕后,滴加2ml稀盐酸淬灭反应,以乙酸乙酯(20ml×3)萃取,合并有机相,分别以1N的盐酸(15ml×2)洗涤,饱和食盐水(15ml×2)洗涤,无水硫酸钠干燥,过滤,滤液减压蒸除溶剂,柱层析(石油醚/乙酸乙酯,70∶30,v/v)纯化得白色固体(5d)0.38g,收率96%。
5d(0.38g,1.09mmol)溶于5mL DMF中,加入H2O(0.5ml),搅拌均匀后加热至100℃反应12h,TLC检测反应完毕后,冷却至室温,将反应液倒入50ml水中,滴加1N稀盐酸调节pH2-3,以乙酸乙酯(20ml×3)萃取,合并有机相,分别以1N的盐酸(15ml×2)洗涤,饱和食盐水(15ml×2)洗涤,无水硫酸钠干燥,过滤,滤液减压蒸除溶剂,柱层析(石油醚/乙酸乙酯,65∶35,v/v)纯化得白色固体(5)0.25g,熔点138-140℃,收率89%。1H NMR(400MHz,DMSO-d6)δ7.65(d,J=7.8Hz,2H),7.62(d,J=8.0Hz,2H),7.50-7.42(m,4H),7.36(t,J=7.3Hz,1H),4.10-4.03(m,1H),2.70(d,J=7.6Hz,2H),1.81(d,J=2.3Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.24,140.91,140.32,139.26,129.38,128.35,127.83,127.24,127.07,80.75,78.98,42.95,33.56,3.71.TOF MS m/z:calcd.for C18H15O2 -[M-H]-:263.1078;found263.1080.
实施例6
3-([1,1′-联苯]-3-基)己-4-炔酸(6)
MHz,DMSO-d6)δ172.29,142.43,140.83,140.56,129.53,129.38,127.94,127.22,126.84,126.26,125.72,80.78,78.99,43.07,34.01,3.69.TOF MS m/z:calcd.forC18H15O2 -[M-H]-:263.1078;found 263.1090.
实施例7
3-([1,1′-联苯]-4-基)-3-环丙基丙酸(7)
7.40(m,2H),7.40-7.28(m,3H),2.76-2.59(m,2H),2.38-2.27(m,1H),1.11-0.98(m,1H),0.61-0.45(m,1H),0.40-0.22(m,2H),0.22-0.10(m,1H).13C NMR(101MHz,DMSO-d6)δ173.53,144.25,140.59,138.57,129.33,128.38,127.62,127.00,126.96,46.52,41.19,18.00,5.50,4.48.TOFMS m/z:calcd.for C18H17O2 -[M-H]-:265.1234;found 265.1237.
实施例8
3-(3-氟-[1,1′-联苯]-4-基)己-4-炔酸(8)
=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.28,160.79(d,J=245.3Hz),142.48(d,J=8.1Hz),139.73,130.25(d,J=4.7Hz),129.38,128.32,127.66(d,J=14.4Hz),127.24,123.20(d,J=3.0Hz),114.00(d,J=23.1Hz),78.98,78.69,41.34,27.95,2.86.TOF MS m/z:calcd.for C18H14FO2 -[M-H]-:281.0983;found 281.0970.
实施例9
3-(2-氟-[1,1′-联苯]-4-基)己-4-炔酸(9)
MHz,DMSO-d6)δ172.55,159.90(d,J=246.1Hz),144.04(d,J=7.5Hz),135.95(d,J=1.1Hz),131.18(d,J=3.8Hz),129.28(d,J=3.0Hz),128.91,128.10,127.78(d,J=13.6Hz),124.19(d,J=3.3Hz),115.52(d,J=23.9Hz),79.59,79.30,42.97,33.79(d,J=1.3Hz),2.88.TOF MS m/z:calcd.for C18H14FO2 -[M-H]-:281.0983;found 281.0989.
实施例10
3-(6-苯基吡啶-3-基)己-4-炔酸(10)
2.5Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.48,155.03,149.18,138.93,136.46,129.34,129.18,127.57,126.88,120.33,80.50,79.08,43.32,31.41,3.69.TOF MS m/z:calcd.for C17H14NO2 -[M-H]-:264.1030;found 264.1042.
实施例11
3-(5-苯基呋喃-2-基)己-4-炔酸(11)
2H),1.79(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.52,154.27,152.42,130.77,129.28,127.70,123.64,108.11,106.90,78.65,78.13,40.69,28.30,3.64.TOF MSm/z:calcd.for C16H13O3 -[M-H]-:253.0870;found 253.0878.
实施例12
3-(5-苯基噻吩-2-基)己-4-炔酸(12)
参照5的合成方法得到化合物12;收率:41%;白色固体;熔点78-80℃;
1H NMR(400MHz,DMSO-d6)δ7.62-7.58(m,2H),7.42-7.38(m,2H),7.32(d,J=3.6Hz,1H),7.31-7.25(m,1H),7.00(d,J=3.6Hz,1H),4.36-4.28(m,1H),2.75-2.69(m,2H),1.81(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.05,145.06,142.09,134,21,129.53,127.90,126.16,125.55,123.63,80.28,78.94,43.69,29.60,3.64.TOF MS m/z:calcd.for C16H13O2S-[M-H]-:269.0642;found 269.0649.
实施例13
3-(4-(吡啶-3-基)苯基)己-4-炔酸(13)
4.23-4.11(m,1H),2.79(d,J=7.6,2H),1.82(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ171.65,148.73,148.22,142.17,136.83,136.47,134.50,128.68,127.54,124.13,80.05,78.93,43.00,34.10,2.89.TOF MS m/z:calcd.for C17H14NO2 -[M-H]-:264.1030;found 264.1043.
实施例14
3-(4-(嘧啶-5-基)苯基)己-4-炔酸(14)
NMR(101MHz,DMSO-d6)δ172.12,157.05,155.04,143.18,134.36,133.23,128.96,127.62,79.88,79.10,42.93,34.04,2.88.TOF MS m/z:calcd.for C16H13N2O2 -[M-H]-:265.0983;found 265.0989.
实施例15
3-(4-(噻吩-2-基)苯基)己-4-炔酸(15)
3.99(m,1H),2.68(d,J=7.6Hz,2H),1.80(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.14,143.51,141.07,132.89,128.91,128.91,128.50,126.00,124.06,80.60,79.05,42.90,33.58,3,69.TOF MS m/z:calcd.for C16H13O2S-[M-H]-:269.0642;found 269.0643.
实施例16
3-(4-(呋喃-2-基)苯基)己-4-炔酸(16)
2.66(d,J=7.6Hz,2H),1.80(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.15,153.32,143.27,140.87,129.50,128.29,124.01,112.48,106.14,80.58,79.04,42.92,33.64,3.69.TOF MS m/z:calcd.for C16H13O3 -[M-H]-:253.0870;found 253.0882.
实施例17
3-(4-(3,5-二甲基异恶唑-4-基)苯基)己-4-炔酸(17)
13C NMR(101MHz,DMSO-d6)δ172.24,165.48,158.57,140.91,129.35,128.88,128.25,116.04,80.66,79.03,42.90,33.63,11.79,10.95,3.68.TOF MS m/z:calcd.forC17H16NO3 -[M-H]-:282.1136;found 282.1139.
实施例18
3-(4-(苯并呋喃-5-基)苯基)己-4-炔酸(18)
Hz,1H),4.12-4.02(m,1H),2.71(d,J=7.6Hz,2H),1.81(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.22,154.39,147.12,140.45,139.68,135.65,128.34,128.31,127.50,123.94,119.72,112.01,107.45,80.79,78.95,42.98,33.55,3.70.TOF MS m/z:calcd.for C20H15O3 -[M-H]-:303.1027;found 303.1021.
实施例19
3-(4-(2,3-二氢苯并呋喃-5-基)苯基)己-4-炔酸(19)
(t,J=8.7Hz,2H),2.66(d,J=7.6Hz,2H),1.80(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.33,159.85,140.03,139.43,132.87,128.59,128.20,126.80,126.70,123.84,109.60,80.96,78.78,71.60,43.23,33.57,29.57,3.70.TOF MS m/z:calcd.for C20H17O3 -[M-H]-:305.1183;found 305.1179.
实施例20
3-(4-(7-甲氧基萘-2-基)苯基)己-4-炔酸(20)
Hz,1H),7.20(dd,J=8.9,2.5Hz,1H),4.12-4.06(m,1H),3.90(s,3H),2.71(d,J=7.6Hz,2H(,1.82(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.21,157.88,140.68,139.17,135.31,134.00,130.17,129.23,128.38,127.81,127.24,125.87,125.40,119.42,106.22,80.79,78.97,55.70,43.00,33.59,3.71.TOF MS m/z:calcd.for C23H19O3 -[M-H]-:343.1340;found 343.1352.
实施例21
3-(4-(6-甲氧基萘-2-基)苯基)己-4-炔酸(21)
(m,3H),7.55-7.35(m,3H),7.21-7.12(m,1H),4.18-4.09(m,1H),3.89(s,3H),2.64(d,J=7.6Hz,2H),1.80(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ174.36,158.02,142.93,138.58,138.31,135.13,129.47,128.64,128.47,128.09,127.20,124.39,123.15,119.01,106.74,82.70,77.71,55.65,46.63,34.50,3.84.TOF MS m/z:calcd.for C23H19O3 -[M-H]-:343.1340;found 343.1334.
实施例22
3-(4-(苯并[d]噻唑-6-基)苯基)己-4-炔酸(22)
参照5的合成方法得到化合物22;收率:32%;白色固体;熔点78-80℃;
1H NMR(300MHz,DMSO-d6)δ9.40(s,1H),8.46(d,J=1.9Hz,1H),8.15(d,J=8.5Hz,1H),7.83(dd,J=8.5,1.9Hz,1H),7.71(d,J=8.1Hz,2H),7.49(d,J=8.1Hz,2H),4.13-4.04(m,1H),2.71(d,J=7.6Hz,2H),1.81(d,J=2.4Hz,3H).13C NMR(75MHz,DMSO-d6)δ172.31,157.01,152.80,141.16,138.62,137.81,135.00,128.48,127.67,125.78,123.68,120.76,80.71,79.06,42.89,33.55,3.72.TOF MS m/z:calcd.for C19H14NO2S-[M-H]-:320.0751;found 320.0738.
实施例23
3-(4-(苯并[d]噻唑-5-基)苯基)己-4-炔酸(23)
4.08(m,1H),2.71(d,J=7.6Hz,2H),1.81(d,J=2.4Hz,3H).13C NMR(75MHz,DMSO-d6)δ172.26,157.49,154.30,141.13,138.79,133.14,130.48,128.49,127.66,124.95,123.39,121.09,80.73,79.02,42.89,33.54,3.73.TOF MS m/z:calcd.for C19H14NO2S-[M-H]-:320.0751found 320.0748.
实施例24
3-(4-吗啉代苯基)己-4-炔酸(24)
J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.30,150.37,132.30,128.23,115.62,81.24,78.40,66.55,49.08,43.27,33.10,3.68.TOF MS m/z:calcd.for C16H18NO3 -[M-H]-:272.1292;found 272.1300.
实施例25
3-(4-(吡咯烷-1-基)苯基)己-4-炔酸(25)
2.4Hz,3H).13C NMR(75MHz,DMSO-d6)δ172.93,147.06,128.46,128.22,111.97,82.04,77.83,47.82,44.41,33.27,2538,3.74.TOF MS m/z:calcd.for C16H18NO2 -[M-H]-:256.1343;found 256.1330.
实施例26
3-(2′-甲基-[1,1′-联苯]-4-基)己-4-炔酸(26)
1.81(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.35,141.40,140.36,140.24,135.15,130.78,129.96,129.47,127.71,127.62,126.38,80.89,78.87,43.25,33.68,20.67,3.71.TOF MS m/z:calcd.for C19H17O2 -[M-H]-:277.1234;found 277.1238.
实施例27
3-(4′-甲氧基-2′-甲基-[1,1′-联苯]-4-基)己-4-炔酸(27)
1H),3.77(s,3H),2.69(d,J=7.6Hz,2H),2.21(s,3H),1.81(d,J=2.4Hz,3H).13CNMR(101MHz,DMSO-d6)δ172.31,158.85,140.03,139.86,136.55,133.89,131.06,129.65,127.55,116.12,111.85,80.84,78.88,55.49,43.08,33.62,20.95,3.70.TOF MS m/z:calcd.for C20H19O3 -[M-H]-:307.1340;found 307.1330.
实施例28
3-(4′-甲氧基-3′-甲基-[1,1′-联苯]-4-基)己-4-炔酸(28)
2.21(s,3H),1.80(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.22,157.46,140.00,139.10,132.24,129.10,128.19,126.67,126.43,125.52,111.14,80.84,78.86,55.80,43.01,33.54,16.63,3.69.TOF MS m/z:calcd.for C20H19O3 -[M-H]-:307.1340;found 307.1327.
实施例29
3-(4′-甲基-[1,1′-联苯]-4-基)己-4-炔酸(29)
(s,3H),1.80(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.23,140.57,139.15,137.41,137.12,129.97,128.29,126.96,126.87,80.77,78.93,42.95,33.54,21.12,3.70.TOF MS m/z:calcd.for C19H17O2 -[M-H]-:277.1234;found 277.1248.
实施例30
3-(3′-氟-[1,1′-联苯]-4-基)己-4-炔酸(30)
Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.34,163.15(d,J=243.2Hz),142.80(d,.J=7.8Hz),141.78,137.77(d,J=2.3Hz),131.27(d,J=8.6Hz),128.41,127.35,123.10(d,J=2.7Hz),114.49(d,J=21.0Hz),113.72(d,J=21.9Hz),80.82,78.93,43.20,33.63,3.69.TOF MS m/z:calcd.for C18H14FO2 -[M-H]-:281.0983;found 281.0994.
实施例31
3-(3′-氯-[1,1′-联苯]-4-基)己-4-炔酸(31)
3H).13C NMR(101MHz,DMSO-d6)δ172.18,142.47,141.64,137.68,134.19,131.19,128.45,127.66,127.41,126.78,125.78,80.64,79.06,42.84,33.56,3.69.TOF MS m/z:calcd.for C18H14ClO2 -[M-H]-:297.0688;found 297.0682.
实施例32
3-(3′-异丙基-[1,1′-联苯]-4-基)己-4-炔酸(32)
参照5的合成方法得到化合物28;收率:36%;白色固体;熔点108-110℃;
1H NMR(400MHz,DMSO-d6)δ8.06-8.01(m,1H),7.84-7.81(m,1H),7.60(d,J=8.3Hz,2H),7.46-7.42(m,3H),7.25-7.22(m,1H),4.08-4.03(m,1H),2.68(d,J=7.6Hz,2H),2.62-2.60(m,1H),1.80(d,J=2.4Hz,3H),1.25(d,J=6.9Hz,6H).13C NMR(101MHz,DMSO-d6)δ172.27,149.51,140.81,140.40,139.60,129.34,128.28,127.32,125.79,125.24,124.64,80.81,78.92,42.98,33.99,27.24,24.37,3.71.TOF MS m/z:calcd.forC21H21O2 -[M-H]-:305.1547;found 305.1458.
实施例33
3-(3′-甲氧基-[1,1′-联苯]-4-基)己-4-炔酸(33)
2.69(d,J=7.6Hz,2H),1.81(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.24,160.18,141.85,141.07,139.16,130.42,128.29,127.35,119.39,113.40,112.61,80.75,78.96,55.56,42.93,33.56,3.70.TOF MS m/z:calcd.for Cl9H17O3 -[M-H]-:293.1183;found 293.1198.
实施例34
3-(3′-乙氧基-[1,1′-联苯]-4-基)己-4-炔酸(34)
4.08(m,3H),2.71(d,J=7.6Hz,2H),1.83(d,J=2.1Hz,3H),1.39(t,J=7.0Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.31,158.86,140.05,139.84,136.56,133.89,131.07,129.65,127.55,116.13,111.86,80.83,78.90,55.50,43.03,33.62,15.95,3.71.TOF MSm/z:calcd.for C20H19O3 -[M-H]-:307.1340;found 307.1324.
实施例35
3-(3′-(二甲氨基)-[1,1′-联苯]-4-基)己-4-炔酸(35)
7.5Hz,2H),1.71(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.23,151.31,141.19,140.65,140.39,129.83,128.14,127.35,115.19,112.01,111.11,80.82,78.90,42.95,40.67,33.58,3.69.TOF MS m/z:calcd.for C20H20NO2 -[M-H]-:306.1500;found306.1492.
实施例36
3-(3′-吗啉代-[1,1′-联苯]-4-基)己-4-炔酸(36)
4.11-4.04(m,1H),3.75(t,J=4.8Hz,4H),3.17(t,J=4.8Hz,4H),2.68(d,J=7.6Hz,2H),1.80(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.23,152.04,141.23,140.80,139.92,129.93,128.17,127.36,118.11,114.73,113.89,80.80,78.92,66.61,48.95,42.97,33.58,3.68.TOF MS m/z:calcd.for C22H22NO3 -[M-H]-:348.1605;found348.1598.
实施例37
3-(3′-(吡咯烷-1-基)-[1,1′-联苯]-4-基)己-4-炔酸(37)
4.04(m,1H),3.28-3.24(m,4H),2.65(d,J=7.6Hz,2H),1.97-1.93(m,4H),1.79(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.50,148.56,141.21,140.80,140.34,129.90,128.13,127.26,114.16,111.28,110.25,81.00,78.79,47.77,43.37,33.67,25.41,3.68.TOF MS m/z:calcd.for C22H22NO2 -[M-H]-:332.1656;found 332.1650.
实施例38
3-(4′-氟-[1,1′-联苯]-4-基)己-4-炔酸(38)
J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.27,162.86(d,J=244.5Hz),141.31,138.99,137.47(d,J=3.2Hz),129.10(d,J=8.1Hz),128.43,127.32,115.92(d,J=21.6Hz),80.14,78.84,43.14,34.01,2.89.TOF MS m/z:calcd.for C18H14FO2 -[M-H]-:281.0983;found 281.0980.
实施例39
3-(4′-氯-[1,1′-联苯]-4-基)己-4-炔酸(39)
(d,J=2.7Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.54,141.77,139.83,138.65,133.27,129.28,128.84,128.52,127.31,80.13,78.86,43.22,34.04,2.91.TOF MS m/z:calcd.for C18H14ClO2 -[M-H]-:297.0688;found 297.0673.
实施例40
3-(4′-(三氟甲基)-[1,1′-联苯]-4-基)己-4-炔酸(40)
(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.34,144.32,142.25,137.57,128.55,128.37,128.05,127.82,127.58,126.19(q,J=3.9Hz),80.77,78.97,43.17,33.65,3.68.TOFMS m/z:calcd.for C19H14F3O2 -[M-H]-:331.0951;found 331.0972.
实施例41
3-(4′-异丙基-[1,1′-联苯]-4-基)己-4-炔酸(41)
2.4Hz,3H),1.23(d,J=6.9Hz,6H).13C NMR(101MHz,DMSO-d6)δ172.27,148.02,140.57,139.24,137.88,128.29,127.31,127.04,127.01,80.78,78.92,42.95,33.56,24.45,24.32,3.71.TOF MS m/z:calcd.for C21H21O2 -[M-H]-:305.1547;found 305.1538.
实施例42
3-(4′-环丙基-[1,1′-联苯]-4-基)己-4-炔酸(42)
-1.92(m,1H),1.80(d,J=2.4Hz,3H),1.00-0.95(m,2H),0.73-0.68(m,2H).13CNMR(101MHz,DMSO-d6)δ172.21,143.49,140.50,139.10,137.25,128.29,126.90,126.87,126.33,80.77,78.93,42.94,33.51,15.25,9.97,3.71.TOF MS m/z:calcd.for C21H19O2 -[M-H]-:303.1391;found 303.1378.
实施例43
3-(4′-(叔丁基)-[1,1′-联苯]-4-基)己-4-炔酸(43)
(s,9H).13C NMR(101MHz,DMSO-d6)δ172.29,150.24,140.60,139.15,137.46,128.31,127.05,126.74,126.16,80.79,78.92,42.93,34.70,33.54,31.57,3.71.TOF MSm/z:calcd.for C22H23O2 -[M-H]-:319.1704;found 319.1714.
实施例44
3-(4′-甲氧基-[1,1′-联苯]-4-基)己-4-炔酸(44)
Hz,2H),1.80(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.26,159.30,140.15,138.90,132.67,128.26,128.12,126.70,114.81,80.83,78.88,55.61,43.03,33.54,3.70.TOF MS m/z:calcd.for C19H17O3 -[M-H]-:293.1183;found 293.1181.
实施例45
3-(4′-(苄氧基)-[1,1′-联苯]-4-基)己-4-炔酸(45)
7.53(d,J=8.3Hz,2H),7.46(d,J=8.3Hz,2H),7.33-7.28(m,2H),7.06-7.01(m,2H),6.94(tt,J=7.2,1.1Hz,1H),5.14(s,2H),4.10-4.03(m,1H),2.69(d,J=7.6Hz,2H),1.80(d,J=2.4Hz,3H).13C NMR(101MHz,DMSO-d6)δ172.24,158.77,141.00,139.79,138.86,136.74,129.97,128.72,128.36,127.21,127.11,121.18,115.24,80.75,78.97,69.19,42.94,33.56,3.71.TOF MS m/z:calcd.for C25H21O3 -[M-H]-:369.1496;found309.1505
实施例46
3-(3′-氟-4′-甲氧基-[1,1′-联苯]-4-基)己-4-炔酸(46)
2.4Hz,3H).(101MHz,DMSO-d6)δ172.23,152.22(d,J=243.6Hz),147.04(d,J=10.6Hz),140.74,137.71,133.26(d,J=6.6Hz),128.33,126.86,123.08(d,J=3.2Hz),114.68(d,J=2.0Hz),114.42(d,J=18.7Hz),80.73,78.96,56.52,42.89,33.51,3.70.TOFMS m/z:calcd.for C19H16FO3 -[M-H]-:311.1089;found 311.1080.
实施例47
3-(4′-(二甲氨基)-[1,1′-联苯]-4-基)己-4-炔酸(47)
3H).13C NMR(75MHz,DMSO-d6)δ172.36,150.28,139.37,139.31,133.22,128.19,127.47,126.04,113.13,80.95,78.78,47.89,43.10,38.42,3.72.TOF MS m/z:calcd.forC20H20NO2 -[M-H]-:306.1500;found 306.1498.
实施例48
3-(3′-氟-4′-(三氟甲基)-[1,1′-联苯]-4-基)己-4-炔酸(48)
(101MHz,DMSO-d6)δ172.21,159.79(d,J=252.4Hz),147.26(d,J=8.6Hz),142.76,136.27,128.60,128.20(d,J=5.2Hz),127.75,124.60,123.40(q,J=3.2Hz),115.71(d,J=12.1Hz),115.45(d,J=21.2Hz),80.50,79.16,42.68,33.54,3.69.TOF MSm/z:calcd.for C19H13F4O2 -[M-H]-:349.0857;found 349.0846.
实施例49
3-(4′-氯-3′-氟-[1,1′-联苯]-4-基)己-4-炔酸(49)
3H).13CNMR(101MHz,DMSO-d6)δ172.23,158.03(d,J=246.1Hz),141.93,141.44(d,J=7.1Hz),136.75(d,J=2.0Hz),131.41,128.49,127.36,124.15(d,J=3.3Hz),118.89(d,J=17.6Hz),115.29(d,J=21.7Hz),80.59,79.08,42.75,33.52,3.70.TOF MSm/z:calcd.for C18H13ClFO2 -[M-H]-:315.0594;found 315.0598.
实施例50
(S)-3-(4′-(三氟甲基)-[1,1′-联苯]-4-基)己-4-炔酸(50)
7.82(d,J=8.1Hz,2H),7.70(d,J=8.1Hz,2H),7.52(d,J=8.1Hz,2H),4.11-4.06(m,1H),2.70(d,J=7.6Hz,2H),1.81(d,J=2.4Hz,3H).TOF MS m/z:calcd.for C19H14F3O2 -[M-H]-:331.0951;found 331.0945.
实施例51
(R)-3-(4′-(三氟甲基)-[1,1′-联苯]-4-基)己-4-炔酸(51)
7.82(d,J=8.1Hz,2H),7.70(d,J=8.1Hz,2H),7.51(d,J=8.1Hz,2H),4.11-4.06(m,1H),2.69(d,J=7.6Hz,2H),1.81(d,J=2.4Hz,3H).TOF MS m/z:calcd.for C19H14F3O2 -[M-H]-:331.0951;found 331.0958.
实施例52
本发明中化合物的FFA1激动活性、体外代谢稳定性实验、SD大鼠的药代动力学特征、组织分布、体内镇痛、ob/ob小鼠糖脂代谢的影响、db/db小鼠脂质代谢相关研究。
以下生物学测试实施例描述解释本发明。
本发明测试例中具体条件的实验方法通常按常规条件或按照商品制造厂商所建议的条件。未注明具体来源的试剂,为市场购买的常用试剂。
测试例1本发明化合物对hFFA1-CHO稳转细胞的FFA1激动活性
本发明使用以下方法测定本发明化合物FFA1的激动活性:
FFA1-CHO稳转细胞以1.5×104/孔的密度接种至96孔板,置于37℃、5%CO2的细胞培养箱过夜培养;弃去培养基,每孔加入100ul HBSS清洗后,加入100ul含Probenecid的Fluo-4染料溶液37℃孵育90min;孵育结束后,吸出Fluo-4染料溶液,加100μl HBSS缓冲液,洗去染料;每孔加入100μl含Probenecid的HBSS,37℃孵育10min;96孔板中每孔加入不同浓度的药物,按照参数设置表用FLIPR(Molecular Devices)读数。分析实验结果。激动活性=(化合物孔荧光值-空白对照孔荧光值)/(亚油酸孔荧光值-空白对照孔荧光值)×100%,结果见表1。
测试例2体外代谢稳定性实验
将受试化合物(1μl,1000ng/mL)、Solution A(10μl)、Solution B(2μl)和0.1MPBS缓冲液(182μl)按比例混匀,于37℃下孵育5分钟,然后加入小鼠、大鼠、比格犬、猴或人肝微粒体(5ul,0.1mg/mL),在37℃下共孵育0,15,30,60,90,120和150min后,加入200μl带有内标的冰甲醇终止反应,取上清液,然后通过LC/MS检测药物浓度并计算药物的半衰期(T1/2)和清除率(CL)。结果见表1和表2。
表1:目标化合物的体外活性及大鼠肝微粒体稳定性(RLM)
ND:Not determined.
结论:本发明化合物对FFA1具有良好的激动活性,且体外肝微粒体稳定性较好(T1/2>15min)。
表2化合物ZLY50在肝微粒体中的体外代谢稳定性
结论:化合物ZLY50在不同种属的肝微粒体中具有优异的体外代谢稳定性。
测试例3体内药代动力学实验
雄性SD大鼠(250±20g)适应性喂养一周后,随机分为2组,每组4只。大鼠禁食12h后称重,分别给大鼠灌胃ZLY50(3mg/kg)或是尾静脉注射ZLY50(1mg/kg)。灌胃给药15,30min及1,2,4,8,12,24,36,48,72,120,168,216,264,312,360,408h后和尾静脉注射给药5,15,30min及1,2,4,8,12,24,36,48,72,120,168,216,264,312,360,408h后,从大鼠眼底静脉丛取约8滴血液,在10000rpm·min-1条件下离心5min,取出上层血浆(50μL),依次加入内标(50μL)和含有0.2%甲酸的乙腈(200μL),涡旋3min后,在14000rpm·min-1条件下离心15min,通过LC/MS检测ZLY50子离子的质谱响应峰面积,利用标准曲线计算得到ZLY50血浆浓度,药代动力学参数通过Phoenix 6.4计算得到。结果见表3。
表3 ZLY50在SD大鼠中的药代动力学特征
结论:ZLY50血浆暴露量高,清除率低,口服半衰期非常长,适合一周给药一次。此外,ZLY50在大鼠中也具有较高的口服生物利用度。
测试例4体内镇痛活性
ZLY50在小鼠辣椒碱舔足模型中的镇痛活性。雄性ICR小鼠(20±2g)适应性喂养一周后,并随机分成5组(每组8只),分别为阴性对照组(Vehicle组),阳性对照组Fenbufen(100mg/kg),待测化合物给药组ZLY50(10,20,40mg/kg)。小鼠禁食12h后称重,实验前45min分别给小鼠灌胃0.5%CMC-Na,Fenbufen(100mg/kg)或ZLY50(10,20,40mg/kg)。实验时在每只小鼠右足背的皮下注射20μl(1.6μg/20μl)辣椒碱溶液,记录5min内小鼠舔右足的总时间。结果见附图2。
ZLY50在小鼠醋酸诱导的扭体模型中的镇痛活性。雄性ICR小鼠(20±2g)适应性喂养一周后,并随机分成5组(每组8只),分别为阴性对照组(Vehicle组),阳性对照组Fenbufen(100mg/kg),待测化合物给药组ZLY50(10,20,40mg/kg)。小鼠禁食12h后称重,实验前45min分别给小鼠灌胃0.5%CMC-Na,Fenbufen(100mg/kg)或ZLY50(10,20,40mg/kg)。实验时小鼠腹腔注射0.2ml 0.6%醋酸溶液,记录小鼠15min内的扭体反应(腹部内凹、伸展后肢、臀部抬高)的次数。结果见附图2。
ZLY50在小鼠热水浴缩尾模型中的镇痛活性。雄性ICR小鼠(20±2g)适应性喂养一周后,并随机分成5组(每组8只),分别为阴性对照组(Vehicle组),阳性对照组Fenbufen(100mg/kg),待测化合物给药组ZLY50(10,20,40mg/kg)。小鼠禁食12h后称重,将ICR小鼠尾巴的三分之一放入52℃热水浴中,记录缩尾响应时间,测量2次(间隔10min),基础痛阈取两次的平均值,尾巴放入热水中的时间不能超过15s。测定基础痛阈40min后,分别给小鼠灌胃0.5%CMC-Na,Fenbufen(100mg/kg)或ZLY50(10,20,40mg/kg)。给药45min后参照基础痛阈的测定并计算出给药后痛阈,最终测得MPE%(percent maximal possible effect)通过以下公式计算:MPE%=(基础痛阈-给药后痛阈/(cut-offtime-基础痛阈)×100,其中cut-offtime为12s。结果见附图2。
结论:如附图1所示,ZLY50对上述三种经典的疼痛模型均具有较好的镇痛效果。
测试例5 ZLY50对ob/ob小鼠糖脂代谢的影响
动物实验分组及处理。雄性ob/ob小鼠(38-42g)适应性喂养一周后,并随机分成5组(每组6只),分别为阴性对照组(Vehicle组),阳性对照组HWL-088(20mg/kg),待测化合物给药组ZLY50(3,6,12mg/kg)和C57老鼠作为正常组(每组6只)。从第一天开始,Vehicle组的小鼠每天一次灌胃0.5%CMC-Na,阳性对照组的小鼠每天一次灌胃HWL-088(20mg/kg),待测化合物给药组的小鼠每周一次灌胃ZLY50(3,6,12mg/kg),给药周期45天。每隔五天测一次空腹血糖和非空腹血糖并且在第1,3和6周进行一次OGTT实验。在治疗结束时,小鼠禁食8h并麻醉后,从小鼠眼底静脉丛取血和收集血液,随后处死小鼠取出胰腺和肝脏,10%生理盐水清洗后,将胰腺和肝脏(统一剪取相同部位)置于组织固定液中进行固定24小时,其余组织放入-80℃冰箱保存备用。结果见附图2。
胰腺和肝脏组织切片。胰腺和肝脏经脱水、石蜡包埋、切取厚度约为4μm、苏木精伊红(H&E)染色、抗胰岛素或抗胰高血糖素抗体进行免疫染色,置于光学显微镜下放大观察胰腺和肝脏组织的病变情况。结果见附图3。
血清生化检测。治疗周期结束取血后,在3500rpm·min-1条件下离心10mm,然后取上清液,使用生化自动分析仪测定谷丙转氨酶(ALT)、谷草转氨酶(AST)、血清总胆固醇(TC)、血清甘油三脂(TG)、以及低密度脂蛋白(LDL)水平。此外,参照TC和TG试剂盒说明书(南京建成)分别测定肝脏TC和TG的含量。结果见附图3。
结论:如附图2所示,ZLY50(每周一次)-对非空腹和空腹血糖水平的降低效果明显优于HWL-088(每天一次),并且在整个研究过程中血糖水平保持稳定,ZLY50可以在胰岛素抵抗的情况下保持降糖作用,并且即使在较低剂量(3mg/kg)下也比每日一次的HWL-088(20mg/kg)提供更好的治疗效果。
如附图3所示,ZLY50改善了肝脏脂肪变性、炎症浸润以及气球样变,尤其ZLY50(12mg/kg)治疗组小鼠肝组织脂肪变性几近消失、气球样变程度和炎症细胞浸润明显减轻,同时也降低肝重比、血清ALT、AST、TC、TG、LDL以及肝脏TC和TG的水平。此外,ZLY50(12mg/kg)能将AST、TC和LDL恢复至接近正常水平。这些结果表明,ZLY50具有改善糖脂代谢的多重疗效,发挥抗脂肪肝作用。
测试例6 ZLY50对db/db小鼠脂质代谢的影响
雄性db/db小鼠(38-42g)适应性喂养一周后,并随机分成5组(每组6只),分别为阴性对照组(Vehicle组),阳性对照组HWL-088(20mg/kg),待测化合物给药组ZLY50(3,6,12mg/kg)和正常C57老鼠作为正常组(每组6只)。从第一天开始,Vehicle组的小鼠每天一次灌胃0.5%CMC-Na,阳性对照组的小鼠每天一次灌胃HWL-088(20mg/kg),待测化合物给药组的小鼠每周一次灌胃ZLY50(3,6,12mg/kg),给药周期30天。在治疗结束时,小鼠禁食8h并麻醉后,从小鼠眼底静脉丛取血和收集血液,并立即处死小鼠取出肝脏,10%生理盐水清洗后,将肝脏(统一剪取相同部位)置于组织固定液中进行固定24h,其余组织放入-80℃冰箱保存备用。肝脏组织切片及生化指标测定方法如测试例5所示。结果见附图4。
结论:如附图4所示,ZLY50改善了脂肪变性、炎症以及气球样变,且ZLY50(12mg/kg)治疗组小鼠肝组织脂肪变性和炎症细胞浸润几近消失、气球样变程度明显减轻,同时也降低肝重比、血清ALT、AST、TC、TG以及肝脏TC、TG和FFA的水平。此外,ZLY50(12mg/kg)能将AST恢复至接近正常水平。这些结果表明,ZLY50具有显著的抗脂肪肝效果。
综上所述,本发明化合物具有良好的FFA1激动活性,且代谢稳定性良好,优选化合物具有改善疼痛、降糖、降脂及改善脂肪肝等的多重功效,具有更广阔的药用开发前景。
Claims (7)
1.通式(I)所示的化合物或其可药用的盐:
其中:
A、B环为各自独立的取代或未取代的苯环、芳杂环;
R1、R2、R3和R4相同或不同,并各自为H、F、Cl、环丙基、二甲氨基、吗啉、哌啶、四氢吡咯、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷基-O-;
R选自H、环丙基、丙炔基。
2.权利要求1所定义的具有通式(I)的化合物或其可药用的盐:
A、B环为各自独立的取代或未取代的苯环、芳杂环;
R1选自H、F、Cl;
R2、R3和R4相同或不同,并各自为H、F、Cl、环丙基、二甲氨基、吗啉、哌啶、四氢吡咯、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷基-O-;
R选自H、环丙基、丙炔基。
3.权利要求1-2所定义的通式(I)化合物或其可药用盐,所述化合物选自:
3-([1,1′-联苯]-4-基)丙酸;
3-([1,1′-联苯]-4-基)己-4-炔酸;
3-([1,1′-联苯]-3-基)己-4-炔酸;
3-([1,1′-联苯]-4-基)-3-环丙基丙酸;
3-(3-氟-[1,1′-联苯]-4-基)己-4-炔酸;
3-(2-氟-[1,1′-联苯]-4-基)己-4-炔酸;
3-(6-苯基吡啶-3-基)己-4-炔酸;
3-(5-苯基呋喃-2-基)己-4-炔酸;
3-(5-苯基噻吩-2-基)己-4-炔酸;
3-(4-(吡啶-3-基)苯基)己-4-炔酸;
3-(4-(嘧啶-5-基)苯基)己-4-炔酸;
3-(4-(噻吩-2-基)苯基)己-4-炔酸;
3-(4-(呋喃-2-基)苯基)己-4-炔酸;
3-(4-(3,5-二甲基异恶唑-4-基)苯基)己-4-炔酸;
3-(4-(苯并呋喃-5-基)苯基)己-4-炔酸;
3-(4-(2,3-二氢苯并呋喃-5-基)苯基)己-4-炔酸;
3-(4-(7-甲氧基萘-2-基)苯基)己-4-炔酸;
3-(4-(6-甲氧基萘-2-基)苯基)己-4-炔酸;
3-(4-(苯并[d]噻唑-6-基)苯基)己-4-炔酸;
3-(4-(苯并[d]噻唑-5-基)苯基)己-4-炔酸;
3-(2′-甲基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-甲氧基-2′-甲基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-甲氧基-3′-甲基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-甲基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(3′-氟-[1,1′-联苯]-4-基)己-4-炔酸;
3-(3′-氯-[1,1′-联苯]-4-基)己-4-炔酸;
3-(3′-异丙基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(3′-甲氧基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(3′-乙氧基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(3′-(二甲氨基)-[1,1′-联苯]-4-基)己-4-炔酸;
3-(3′-吗啉代-[1,1′-联苯]-4-基)己-4-炔酸;
3-(3′-(吡咯烷-1-基)-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-氟-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-氯-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-(三氟甲基)-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-异丙基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-环丙基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-(叔丁基)-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-甲氧基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-(苄氧基)-[1,1′-联苯]-4-基)己-4-炔酸;
3-(3′-氟-4′-甲氧基-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-(二甲氨基)-[1,1′-联苯]-4-基)己-4-炔酸;
3-(3′-氟-4′-(三氟甲基)-[1,1′-联苯]-4-基)己-4-炔酸;
3-(4′-氯-3′-氟-[1,1′-联苯]-4-基)己-4-炔酸;
(S)-3-(4′-(三氟甲基)-[1,1′-联苯]-4-基)己-4-炔酸;
(R)-3-(4′-(三氟甲基)-[1,1′-联苯]-4-基)己-4-炔酸。
4.一种药物组合物,含有权利要求1-3所述的化合物或其可药用盐,及适当的载体或赋形剂。
5.权利要求1-3所定义的化合物或其可药用的盐、或权利要求4所述药物组合物在制备治疗FFA1受体介导疾病的药物中的用途。
6.权利要求1-3所定义的化合物或其可药用的盐、或权利要求4所述药物组合物在制备预防或/和治疗葡萄糖代谢异常或/和脂质代谢异常疾病的药物中的用途。
7.权利要求1-3所定义的化合物或其可药用的盐、或权利要求4所述药物组合物在制备预防或/和治疗糖尿病、肥胖症、高血脂、炎症性肠病、疼痛、癌症恶病质、阿尔兹海默症、胆汁淤积性肝病、线粒体病、酒精性肝病、药物性肝损伤、糖尿病并发症、前驱糖尿病、器官纤维化、动脉粥样硬化及脂肪肝中至少一种疾病的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210340242.XA CN116924906A (zh) | 2022-03-31 | 2022-03-31 | 一种新型长效ffa1激动剂、其制备方法及其作为药物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210340242.XA CN116924906A (zh) | 2022-03-31 | 2022-03-31 | 一种新型长效ffa1激动剂、其制备方法及其作为药物的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116924906A true CN116924906A (zh) | 2023-10-24 |
Family
ID=88376021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210340242.XA Pending CN116924906A (zh) | 2022-03-31 | 2022-03-31 | 一种新型长效ffa1激动剂、其制备方法及其作为药物的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116924906A (zh) |
-
2022
- 2022-03-31 CN CN202210340242.XA patent/CN116924906A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101106631B1 (ko) | 대사 질환의 치료용 화합물 | |
CA2521621C (en) | Compounds for the treatment of metabolic disorders | |
NZ568048A (en) | Compounds for the treatment of metabolic disorders | |
EP2914580B1 (en) | Thioaryl derivatives as gpr120 agonists | |
JP2010524932A (ja) | 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸gpr40調節物質 | |
JP2007502815A (ja) | Ppar調節因子 | |
CA2637884A1 (en) | Compounds for the treatment of metabolic disorders | |
EP1618086B1 (en) | Compounds for the treatment of metabolic disorders | |
EP1868595B1 (en) | Compounds for the treatment of metabolic disorders | |
WO2013139341A1 (en) | Gpr120 receptor modulators | |
WO2013185766A1 (en) | Gpr120 receptor modulators | |
KR20040081107A (ko) | 페닐(알킬)카르복시산 유도체 및 디이온성페닐알킬헤테로사이클릭 유도체, 및 혈청 글루코스및/또는 혈청 지질 강하 활성을 갖는 약제로서의 그의 용도 | |
CN112759515B (zh) | 一种新型FFA1和PPARα/γ/δ四重激动剂、其制备方法及其作为药物的用途 | |
CN116924906A (zh) | 一种新型长效ffa1激动剂、其制备方法及其作为药物的用途 | |
WO2012145899A1 (zh) | 酯类化合物、其制备方法和应用 | |
CN109456274B (zh) | 苯并咪唑类衍生物、其制备方法及其作为药物的用途 | |
EP1836150B1 (en) | Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof | |
JPWO2006022237A1 (ja) | 脂肪肝の予防または治療剤 | |
CN101092415B (zh) | 一类新的苯并杂环类化合物、其制备方法和用途 | |
Sweidan et al. | Synthesis and In Vivo Hypolipidemic Effect of Some N-(Benzoylphenyl)-Carboxamide Derivatives in Triton WR-1339-Induced Hyperlipidemic Rats | |
CN107162913B (zh) | 一类新型氘代苯丙酸衍生物、其制备方法及其作为药物的用途 | |
RU2712624C2 (ru) | Композиции для лечения заболевания почек и/или печени | |
EP1836187B1 (en) | 1h-indole-3-carboxylic acid derivatives and their use as ppar agonists | |
EP0518769B1 (fr) | Nouveaux dérivés de benzoate d'éthanolamine, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
WO2011075935A1 (zh) | 二苯基乙烯类衍生物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |